I agree, and you know how I know CYDY is shady? They don't have any cash, enough cash for the HIV programs. What do they do? Go out and add breast cancer, colon cancer, NASH, etc.
What CYDY needed to do is just focus on getting the HIV through the finish line first. Then worry about other indications.
Look, I know biotechs. They all tend to have big pipelines but difference is they trade on the NASDAQ and find solid institutional funding and have lots of cash on hand. CYDY refuses to uplist to get better capital, trades on the OTC which puts them financing with vultures and they barely have cash to get by. Why add more programs, when they don't even have the cash on hand to get the HIV product to the finish line? They gotta worry about commercialization and other issues. To me it's always been fishy why they never wanted off the OTC and now I know why. Don't get me started on the salary that the CEO Pourhassan makes, which is absurd for a company that doesn't yet make any money.
News 
Market Data 
Discover 
AI
